NCT06565572View on ClinicalTrials.gov

Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

August 21, 2024

Study Completion Date

December 31, 2028

Conditions
Posterior Column Ataxia with Retinitis Pigmentosa
Interventions
DRUG

nL-FLVC-001

nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous

Trial Locations (1)

80045

Childrens Hospital Colorado, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER